Efinaconazole - Valeant Pharmaceuticals International

Drug Profile

Efinaconazole - Valeant Pharmaceuticals International

Alternative Names: Clenafin; IDP-108; Jublia; KP-103

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kaken Pharmaceutical
  • Developer Dong-A ST; Kaken Pharmaceutical; Tai Tien Pharmaceuticals; Valeant Pharmaceuticals International
  • Class Antifungals; Piperidines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Onychomycosis

Most Recent Events

  • 19 Jun 2018 Registered for Onychomycosis in Taiwan (Topical)
  • 18 Jun 2018 TFDA grants Marketing Authorisation of Efinaconazole for Onychomycosis treatment in Taiwan
  • 07 Jun 2018 The USPTO issued a final decision in favour of Argentum Pharmaceuticals filed against Valeant Pharmaceutical for all claims of US Patent number 7 214 506 ('506 patent) to be unpatentable in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top